Biomarkers: From n=1 to 7 Billion
By Anthony Rowe, Principal Scientist – R&D IT External Innovation, Janssen R&D.
Speaker for our 4th Annual Symposium:
Talk time: 10:30 am 27.3.2014
Talk abstract: "In recent years we have seen an large increase in the use of omics technologies applied to large scale cohort studies to help discover potential biomarkers of disease detection, prognosis or response to therapy. In this talk we will show how we start to scale this type of experimental approach to larger numbers of patients by considering how biomarker approaches can integrate with electronic healthcare records as a way to combine these two approaches. Finally well conclude by offering perspectives how to gain further insights at a populations scale by using digital biomarkers."
Bio: "Anthony Rowe works as a principal research scientist in the Janssen R&D IT – External Innovation Group. His current role is to explore the new business models and informatics technologies to support biomarker discovery and translational research. He currently participates in eight different biomarker discovery public-private partnerships across Immunology, Oncology, Infectious disease and Neurosciences research areas with a focus on the informatics needed to best leverage new high dimensional biology profiling technology. Dr Rowe has been working in the field of translational informatics and knowledge management for over 10 years. He has had roles in the three primary stakeholders that make up the biomarker discovery eco-system: academia, SMEs and Pharmaceutical companies."